The Parent-of-Origin Phenomena in Congenital Muscular Dystrophy


Recent Posts



CMD-resizeMuscular Dystrophy Canada is passionate about finding treatments and improving the quality of life for Canadians affected by over 150 different types of neuromuscular disorders. In order to do this, we have been dedicated to funding biomedical and discovery research to increase our understanding about these genetic disorders. Research has been successful at uncovering the causes and mechanisms behind several neuromuscular disorders, like Duchenne muscular dystrophy, there are still many unanswered questions with other conditions, like myotonic dystrophy.

Myotonic dystrophy is a rare disease. The worldwide prevalence is 14 per 100,000 people;, however, it is 30 to 60 times more common in the Saguenay-Lac-Saint-Jean region of Quebec, where the prevalence is 189 per 100,000. Myotonic dystrophy type I (DM1) has both an adult form and a congenital form. Congenital myotonic dystrophy, the most severe form of myotonic dystrophy, is almost always inherited from an affected mother; affected fathers rarely have children with the congenital form. Now, thanks to a study published in the March 2 online edition of The American Journal of Human Genetics (AJHG), there is an explanation for this “parent-of-origin” phenomena.

The study conducted by Muscular Dystrophy Canada funded researcher Christopher Pearson (Sick Kids), and Vrije Univesriteit Brussel (Belgium), found that the DNA in the mother’s eggs show a chemical change called methylation, which causes this severe form of the disorder in children inheriting the disorder from their mothers. They showed that in fathers, this methylation inhibits sperm production, which is actually a protective factor that prevents the condition from being passed down from an affected father to a child.

The Pearson research team aims to use this specific methylation in the DNA to develop a diagnostic marker for prenatal testing.  Currently there is no definitive test for congenital myotonic dystrophy. Knowing that a pregnancy will result in the congenital form of the disorder will allow families to make informed decisions and prepare for the known possible outcomes.

Dr. Pearson’s lab, which has received several research grants from Muscular Dystrophy Canada’s Rachel Fund for myotonic dystrophy, is also working to find a therapeutic intervention. They are investigating drugs that would arrest or reverse the disease progression by stopping the CTG expansions that drive the progressive nature of myotonic dystrophy.



Looking for more resources about mytonic dystrophy? Check out our website or call 1-866-687-2538 to speak with our caring and knowledgeable services team.






Posted on:

2 Responses

  1. Kathleen Robertshaw says:

    MD has notified us of your research on myotonic dystrophy. I have two adult children with the disease which was passed from their father. Their grandmother was the carrier to start this in our family. Are there any new developments in the way of medications that can help both of them. My daughter is worse than her brother but both have difficulty walking, using hands, back problems, etc. and are under the care of a neurologist. As we were part of the research to identify the gene for myotonia I am wondering if you have any further news on the research that ciould help both my children. Thanks Kathleen Robertshaw

    • musclecanada says:

      Hi Kathleen,

      Unfortunately, no new treatments are available, but research and clinical study work is underway. Though there are currently no clinical trials in Canada relating to Myotonic dystrophy, you can visit and search for Myotonic Dystrophy for a complete list of studies being done in the United States.

Leave a Reply

WP-Backgrounds by InoPlugs Web Design and Juwelier Schönmann